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ABSTRACT
Objective: Our aim is comparison of hemodynamic status and complications between two different doses of intramyometrial vasopressin during 
laparoscopic myomectomy.
Methods: We did a retrospective analysis of hemodynamic status and its anesthetic concerns in patients who received two different doses of 
intramyometrial vasopressin. Eighty patients undergoing laparoscopic myomectomy under general anesthesia were divided into two groups of 
40 patients in each group. In Group A (n=40), 10 units of intramyometrial vasopressin in 200 ml of normal saline were given and, in Group B, 20 units 
of intramyometrial vasopressin in 200 ml of NS were given intraoperatively by surgeon.
Results: 20 units intramyometrial vasopressin used dogmatically by surgeons drops blood loss but it is connected with cardiovascular impediments. 
Hence, 10 units of intramyometrial vasopressin as compared to 20 units which are used by some surgeons are associated with similar blood loss and 
lesser side effects such as bradycardia, pulmonary edema, hypotension, blood loss, and increased airway pressure.
Conclusion: Hence, anesthesiologists and gynecologists must take the precautions to escape and minimize the frequency of impediments with 
intramyometrial vasopressin by selecting the appropriate dosage of vasopressin.
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INTRODUCTION
Uterine leiomyoma is the most extensively recognized sort of pelvic 
tumors in women [1].When a uterine myoma creates, the ordinary 
life systems of uterine veins are disturbed, and the vessels run in 
unusual ways. Myomectomy causes vascular injury paying little heed 
to the bearing of the entry point and results in extreme blood loss [2]. 
Vasopressin is a synthetic analog of the anti-diuretic hormone; it causes 
vasoconstriction through its activity on V1 receptors and against 
diuresis through V2 receptors in the kidney [3]. Intramyometrial 
infusion of vasopressin causes vasoconstriction, stimulates the 
uterine contractions and therefore it reduces the blood loss during 
surgery [4,5]. However, vasopressin was reported to be associated with 
severe complications such as bradycardia, arrhythmias, pulmonary 
edema, and cardiac arrest [6-9]. The variations in heart rate (HR) and 
blood pressure after intramyometrial vasopressin injection might 
be correlated to the systemic absorption of vasopressin especially 
during the surgical excisions of the fibroid and not linked to the direct 
intravascular injection. Studies have proven that vasopressin was 
injected after negative blood aspiration during injection and second 
the hemodynamic changes did not happen during vasopressin injection 
but after 10 min of vasopressin injection in most of the cases. The 
injection of diluted vasopressin into the plane between the myoma 
and myometrium leads to vasoconstriction of the feeding vessels for 
45–60 min which is usually sufficient for the myometrial suturing to 
be accomplished and therefore reducing the blood flow to the myoma 
and lessening the blood loss during the excision of the myoma [10- 12]. 
There are discussions and encounters between the surgeons and 
anesthesiologists regarding the risks and advantages of vasopressin 
and therefore, this study was conducted to evaluate the incidence of 
cardiovascular complications associated with the intramyometrial 
injection of vasopressin. Hence, our aim here is to look for the changes 
in hemodynamic status and complications after two different doses of 
intramyometrial vasopressin and to look for any difference in blood loss 
in both groups.
METHODS
It is a retrospective observational study at the Department of 
Anesthesiology, Institute of Medical Sciences and SUM Hospital. Data 
were collected from April 2017 to July 2018 at MRD department of IMS 
and SUM hospital after obtaining approval from the institutional ethical 
committee. A total of 80 patients undergoing laparoscopic myomectomy 
under general anesthesia were divided into two groups of 40 each. In 
Group A (n=40), 10 units of intramyometrial vasopressin in 200 ml 
of NS were used and, in Group B (n=40), 20 units of intramyometrial 
vasopressin in 200 ml of NS were used for infiltration by surgeon.
Inclusion criteria




Standard balanced general anesthesia and Standard monitoring 
techniques were followed.
Within 2–3 min of injection of intramyometrial vasopressin, there 
was decrease in the HR (<50), along with a significant drop in the 
mean arterial pressures (<60 mmHg). However, there was no change 
in the electrocardiogram or the endtidal carbon dioxide (EtCO2) 
waveform and its values. These changes are more marked in patients 
in Group B. The changes reverted back to baseline in 15–25 min time 
as documented.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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Following data were collected for the study purpose
•	 General	information	about	the	patients	such	as	age,	sex,	height,	and	
weight including duration of surgery and anesthesia
•	 Baseline	vital	parameters	 such	as	HR	and	blood	pressure	 (mean	
arterial pressure) noted in all patients preoperatively
•	 Intraoperative	HR,	 systolic	 and	diastolic	blood	pressure,	oxygen	
saturation,	ETCO₂,	and	airway	pressures	were	noted	starting	from	










Data were collected and entered into Microsoft Excel 2007 and analysis 
was performed using SPSS version 20.0. The entire categorical variable 
was expressed in terms of number and percentages. Comparison 
between categorical variables was performed using Chi-square test. 
All continuous variables were expressed in terms of mean and SD. 
Comparison between continuous variables was performed using 
unpaired t-test. p<0.05 was considered statistically significant.
RESULTS
In our study, we found that the demographic profile of both the groups 
was similar in terms of age, weight, height, duration of surgery, and 
duration	of	anesthesia	with	p>0.05	(Table	1).
Blood loss was almost similar in both the groups. Group A had 
mean blood loss of 264±20.43 ml and Group B had mean blood loss 
of 213±18.35 ml. The p-value between two groups is 0.601 which is 
statistically insignificant. Bradycardia and hypotension occurred in 
50% of Group B patients as compared to 20% in Group A patients 
with *p-=0.034 which is statistically significant. Airway pressure was 
increased in 12.5% patients of Group B as compared to 2.5% in Group A, 
the difference being statistically significant with *p-value=0.041. 
Pulmonary edema occurred in 10% of Group B patients and none of 
Group A patients, p-value being different statistically, *p-value=0.04 
(Table 2 and Fig. 1).
DISCUSSION
One of the key attentions for the doctors during resection of significantly 
vascular tumors such as uterine myomas (fibroid) is extreme bleeding 
that might be life threatening. Several mechanical and pharmacological 
interventions are used to diminish blood loss. Vasopressin is an 
hemostatic agent recycled for over and above 50 years, and there are 
published data reports supporting the usage of vasopressin to decrease 
blood loss during myomectomy. Likewise, there are published reports of 
adverse cardiac events that include cardiac arrest following vasopressin 
management [13-15]. These cardiac results are potentiated in patients 
with coronary insufficiency. Vasopressin causes decreased HR and 
decreased cardiac output due to coronary vasoconstriction, potentiated 
baroreflex due to generalized vasoconstriction. Although it causes global 
vasoconstriction, it clinically manifests as global hypotension [16]. 
Failure to identify this will lead to treatment with vasopressors that 
can worsen the cardiac complications. The hemostatic property of 
vasopressin is well addressed in many studies, but the safe total dose 
and concentration is still controversial [17,18]. Frishman recommended 
intramyometrial dose of 4–6 U at a concentration 0.2 U/ml to be safe, 
based on assumption that low dose and low concentration are equally 
effective in achieving hemostasis without cardiac complications [19]. In 
our study, we also found that less complications occur with low doses 
(Table 2 and Fig. 1). 10 units of vasopressin causes similar blood loss 
as compared to 20 units with lesser side effects such as hypotension, 
bradycardia, pulmonary edema, and increased airway pressures.
Limitations
We have studied a smaller group of population which may not provide 
the accurate result. We have done a retrospective analysis so real 
time assessment of problems could not be done. Large-scale trials 
should be done on intramyometrial dose and concentration to find 
out the safe dose and concentration of vasopressin. A prospective 
study should be done to analyze and compare the doses. We report 
these studies to alert the anesthesiologists so that guidelines can be 
framed regarding the dose, concentration and the continued use of 
vasopressin and if there are any other alternatives to vasopressin 
available.
CONCLUSION
Guidelines including the safe dose and concentration of intramyometrial 
vasopressin and proper patient selection are warranted. Close 
communication between the anesthesiologist and gynecologist 
regarding correct dose of vasopressin is of paramount importance to 
prevent, identify and treat the complications related to intramyometrial 
vasopressin infiltration. If lesser dose of intramyometrial vasopressin 
injection is causing similar blood loss with lesser side effects, then it is 
a matter of concern while selecting the appropriate dosage.
Table 2: Comparison between incidences of adverse events in 
both the groups





Bradycardia 08 (20%) 20 (50%) 0.034
Hypotension 08 (20%) 20 (50%) 0.034
Increased airway 
pressure
01 (2.5%) 05 (12.5%) 0.041
Arrhythmia 00 00 --
Pulmonary edema 00 04 (10%) 0.04
Blood loss (ml) 264±20.43 213±18.35 0.601
*Chi-squared test was used to calculate p-value
Table 1: Demographic profile of both the patient Groups A and B 
with duration of surgery and anesthesia







Age (in years) 40.12±5.23 41.04±4.23 0.456
Weight (kg) 65.3±4.56 66.2±5.65 0.543
Height (cm) 160.5±10.65 162.5±11.57 0.488
Duration of surgery 
(min)
45.6±12.43 46.4±13.23 0.786
Duration of anesthesia 
(min)
60.23±10.15 62.54±11.21 0.406
*Unpaired t-test was used
Fig. 1: Adverse effect with two doses of vasopressin
113
Asian J Pharm Clin Res, Vol 14, Issue 10, 2021, 111-113
 Moda et al.
AUTHORS CONTRIBUTION
1. Dr. Nupur Moda-Acquisition of data, writing manuscript, 
interpretation of data
2. Dr. Sushree Das-Acquisition of data, concept and designing, data collection








1. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin 
Pathol 1990; 94:435-8.
2. Zeqja E, Qirko R. Vasopressine in laparoscopic myomectomy, a review 
over the effectiveness, dosage and possible complications. IOSR J 
Pharm 2016; 6:23-7.
3. Wing DA, Goharkhay N, Felix JC, Rostamkhani M, Naidu YM, 
Kovacs BW. Expression of the oxytocin and V1a vasopressin receptors 
in human myometrium in differing physiologic states and following 
misoprostol administration. Gynecol Obstet Invest 2006; 62:181-5.
4. Shimanuki H, Takeuchi H, Kitade M, Kikuchi I, Kumakiri J, Kinoshita K. 
The effect of vasopressin on local and general circulation during 
laparoscopic surgery. J Minim Invasive Gynecol 2006;  13:190- 4.
5. Takeuchi H, Shimanuki H, Kobori H, Kitade M, Kikuchi I, Kinoshita K. 
Effect of vasopressin on blood flow and RI of the uterine artery during 
laparoscopic myomectomy. J Minim Invasive Gynecol 2005; 12:10-1.
6. Nezhat F, Admon D, Nezhat CH, Dicorpo JE, Nezhat C. Life-
threatening hypotension after vasopressin injection during operative 
laparoscopy, followed by uneventful repeat laparoscopy. J Am Assocc 
Gynecol Laparosc 1994; 2:83-6.
7. Hobo R, Netsu S, Koyasu Y, Tsutsumi O. Bradycardia and cardiac 
arrest caused by intramyometrial injection of vasopressin during 
a laparoscopically assisted myomectomy. Obstet Gynecol 2009; 
113:484- 6.
8. Kimura T, Kucui C. Effectiveness of hormonal tourniquet by 
vasopressin during myomectomy through vasopressin V1a receptor 
ubiquitously expressed in myometrium. Gynecol Obstet Invest 2002; 
54:125-31.
9. Park KS, Yoo KY. Role of vasopressin in current anesthetic practice. 
Korean J Anesthesiol 2017; 70:245-57.
10. Tsuda A, Kanaoka Y. Submyometrial vasopressin injection before 
microwave ablation of vascular-rich submucosalmyomas: A preliminary 
case study. Int J Hyperthermia 2019; 36:739-43.
11. Kakkar B. Is Irrational use of intramyometrial vasopressin justified in 
anesthesia practice? Anaesth Commun 2017; 1:e102.
12. Malla UJ, Rong ZS. Role of vasopressin in myomectomy. IJSIT 
2018; 7:183-7.
13. Dillon TF, Marbury BE, Bonsnes RW, Douglas RG, DuVigneaud V. 
Vasopressin as a hemostatic in gynecologic surgery; a preliminary 
report. Obstet Gynecol 1958; 11:363-71.
14. Fletcher H, Frederick J, Hardie M, Simeon D. A randomized 
comparison of vasopressin and tourniquet as hemostatic agents during 
myomectomy. Obstet Gynecol 1996; 87:1014-8.
15. Jayaraman L, Sinha A, Punhani D. Intramyometrial vasopressin: 
Anesthesiologists’ nightmare. J Anaesthesiol Clin Pharmacol 
2013; 29:135-6.
16. Riess ML, Ulrichs JG, Pagel PS, Woehlck HJ. Case report: Severe 
vasospasm mimics hypotension after high-dose intrauterine vasopressin. 
Anesth Analg 2011; 113:1103-5.
17. Barett KE, Boitano S, Barman SM, Brooks HL. Ganong’s Review of 
Medical Physiology. 24th ed. New York: McGraw-Hill; 2012.
18. American Heart Association. Guidelines for cardiopulmonary 
resuscitation and emergency cardiovascular care: Part 7.3: Management 
of symptomatic bradycardia and tachycardia. Circulation 2005; 
112:67- 77.
19. Frishman G. Vasopressin: If some is good, is more better? Obstet 
Gynecol 2009; 113:476-7.
